- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04776577
Assessment of Coronary Pressure Using the Combined Guidewire and Catheter Wirecath
Study Overview
Status
Conditions
Detailed Description
Simultaneous measurements study (group 1) This group will be recruited and assessed in parallel with recruitment to group 2 at the discretion of the treating physician, based on the resource availability in the cath lab.
In the simultaneous measurements study group, measurements will be collected from a Wirecath® and a regular sensor-tipped pressure wire in the same position in the coronary artery at the same time (simultaneously). The regular wire to be used is the market leading Abbott PressureWire®.
By comparing the pressure measurements (Pd) from Wirecath® and from a regular sensor-tipped wire, we intend to examine if the pressure reported by the two wires deviate in any way. If a deviation exists, the hydrostatic error, caused by the height difference between the positions of Pa and Pd when using a sensor-tipped wire, will be assessed.
In FFR-negative patients, after removal of the Wirecath®, the Abbott PressureWire® is used in LAD
- first to measure CFR by saline bolus injections and thermodilution during rest and hyperemia (Bolus-thermo CFR) and
- second together with a Hexacath/Rayflow@ infusion catheter and a saline infusion pump to measure absolute flow during rest and hyperemia that will be used to calculate CFR (Absolute-flow CFR).
Wirecath will be used for PCI when indicated and performance documented by follow-up questions to the users.
Regular study group (group 2) In the regular use study group, the Wirecath® is to be used as a regular pressure measurement tool, replacing the regularly used pressure wire.
Pressure measurement results will be collected.
Wirecath® will be used for PCI when indicated and performance documented by follow-up questions to the users.
In FFR-negative patients, after removal of the Wirecath®, the Abbott PressureWire® is used in LAD
- first to measure CFR by saline bolus injections and thermodilution during rest and hyperemia (Bolus-thermo CFR) and
- second together with a Hexacath/Rayflow® infusion catheter and a saline infusion pump to measure absolute flow during rest and hyperemia that will be used to calculate CFR (Absolute-flow CFR).
Echocardiography-CFR group (group 3) Patients from group 1 and group 2 that have undergone Bolus-thermo and Absolute-flow CFR measurements, will be recruited to group 3. In this group echocardiography-CFR (Echo CFR) will be measured within 14 days. The echocardiography is performed according to the standard procedure of the hospital. The correlation between the methods will be investigated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mats Hilmersson
- Phone Number: +46 704931307
- Email: mats.hilmersson@cavistechnologies.com
Study Locations
-
-
-
Gothenburg, Sweden, 41345
- Sahlgrenska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (>18yrs age)
- Informed consent given
- Patients with result from diagnostic angiography
- Indication for coronary pressure assessment
Exclusion Criteria:
- Patients with known Heparin-Induced Thrombocytopenia (HIT) or allergy to heparin.
- Inability to tolerate Adenosine
- Any condition, e.g. unstable health, which in the opinion of the investigator makes the patient unsuitable for inclusion (Decision documented in inclusion log).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Study arm
Group 1 and group 2 will be recruited and assessed in parallel at the discretion of the treating physician, based on the characteristics of the patient. Group 3 will be recruited from suitable patients in group 1 and 2. Simultaneous measurements study (group 1) Regular study group (group 2) Echocardiography-CFR group (group 3) |
Simultaneous FFR measurements with Wirecath@ and Abbott PressureWire®
FFR measurement with Wirecath® only
Pressure derived CFR with Wirecath®, Thermodilution CFR with Abbott PressureWire®, Absolut flow CFR with Abbott PressureWire® and Hexacath Rayflow catheter®, Non-invasive echo derived CFR
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of the Wirecath® will be assessed through the frequency and severity of all adverse events
Time Frame: 30-60 minutes
|
The safety of the Wirecath@ will be assessed through the frequency and severity of all adverse events reported for study subjects after the completion of the pressure measurement and PCI.
The primary endpoint will be achieved when the device has been used on enrolled patients and required measurements have been taken.
|
30-60 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison with Abbott pressure wire
Time Frame: 30-60 minutes
|
comparing the Wirecath measurement values with the measurement values of a regular sensor-tipped pressure guidewire during simultaneous measurements in the same vessel.
|
30-60 minutes
|
Comparing pressure-derived coronary flow reserve (CFR) with bolus-thermo CFR, absolute flow CFR and non-invasive doppler derived CFR
Time Frame: 14 days
|
In FFR negative LADs, comparing the Wirecath® pressure-derived CFR values with CFR derived from thermodilution, absolute flow and echocardiography-CFR values.
This secondary endpoint will be achieved if these values correlate
|
14 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Oskar Angerås, MD PhD, Sahlgrenska University Hospital, Gothenburg, Sweden
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0100P
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
National Heart Centre SingaporeUnknownCoronary Heart DiseaseSingapore
Clinical Trials on Wirecath@ and Abbott PressureWire® (20 patients)
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; King's College Hospital NHS TrustRecruitingCoronary Artery Disease | ST Elevation Myocardial Infarction | Ischemic Heart DiseaseUnited Kingdom
-
RIVAGESNot yet recruitingChronic Disease | Medication Compliance | Polypathology | Elderly Person | Digital Application
-
Universidad del ZuliaCompleted
-
University of Southern CaliforniaWallace H. Coulter Foundation; Halyard HealthCompleted
-
Universiti Sains MalaysiaCompleted
-
Assistance Publique - Hôpitaux de ParisUnknownAdult Patients Living With HIV (PLWHIV) With Confirmed Infection With SARS-CoV-2 Since 1st January 2020France
-
Sam Houston State UniversityChelsea Ratcliff, Ph.D.; Owen Kelly, Ph.D.,RNutr; Oluwaseun Olaiya, DO; Michael...RecruitingType 2 DiabetesUnited States
-
Jena University HospitalGerman Research Foundation; Instituto Grifols, S.A.; University Hospital Goettingen and other collaboratorsRecruiting
-
Jinsheng HongZhongshan Hospital Xiamen University; Fujian Cancer Hospital; Hunan Cancer Hospital and other collaboratorsRecruitingEffect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal CarcinomaNasopharyngeal Carcinoma | Nutritional SupportChina
-
Klinikum LudwigshafenCompletedInflammatory Response | Hepatic FunctionGermany